Brief: Erasca Provides Update On Clinical Program For ERK Inhibitor ERAS-007

Erasca

05/06/2023 21:33

June 5 (Reuters) - Erasca Inc  ERAS.O :
    * ERASCA PROVIDES UPDATE ON CLINICAL PROGRAM FOR ERK
INHIBITOR
ERAS-007 AND REFINES PIPELINE
    * ERASCA INC-ERAS-007 + EC WAS GENERALLY WELL TOLERATED WITH
MOSTLY LOW-GRADE TREATMENT-RELATED ADVERSE EVENTS (TRAES) AT ALL
COMBINATION DOSES TESTED
    * ERASCA - NAPORAFENIB, ERAS-007, ERAS-601, AND ERAS-801
PROGRAMS
IN THOSE WITH RAS/MAPK PATHWAY-DRIVEN TUMORS OFFER POTENTIAL
DIFFERENTIATION
    * ERASCA - NAPORAFENIB, ERAS-007, ERAS-601, AND ERAS-801
PROGRAMS
IN THOSE WITH RAS/MAPK PATHWAY-DRIVEN TUMORS OFFER NEAR-TERM
CATALYSTS
    * ERASCA INC - DEPRIORITIZED HERKULES-2 AS CLINICAL EFFICACY
DATA
DO NOT SUPPORT CONTINUED EVALUATION
    * ERASCA INC -  DEPRIORITIZED HERKULES-3: ERAS-007 +
PALBOCICLIB
STUDY AS CLINICAL EFFICACY DATA DO NOT SUPPORT CONTINUED
EVALUATION

Source text for Eikon:  ID:nGNX7MKc4Q 
Further company coverage:  ERAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))